about
Inflammatory breast cancer: clinical progress and the main problems that must be addressedReactive oxygen species: role in the development of cancer and various chronic conditionsOn how CCN6 suppresses breast cancer growth and invasionWISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancerUpdate on inflammatory breast cancerMolecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.DNA Damage Response and Immune Defense: Links and MechanismsOsteoprotegerin rich tumor microenvironment: implications in breast cancerCytotoxic and Antitumor Activity of Sulforaphane: The Role of Reactive Oxygen SpeciesInflammatory breast cancer: New factors contribute to disease etiology: A reviewDevelopmental therapeutics for inflammatory breast cancer: Biology and translational directionsRUNX1 and its understudied role in breast cancerIn vivo lymphatic imaging of a human inflammatory breast cancer model.Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.NF-kappa B genes have a major role in inflammatory breast cancerArray-based DNA methylation profiling for breast cancer subtype discrimination.AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer modelsIntegrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtypeAlternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signalingOverall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosisPhase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas.WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancerRhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancerInflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer.Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.Prognostic significance of HER-2 status in women with inflammatory breast cancerNeoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinctionp53 mutations and overexpression in locally advanced breast cancersDiverse presentations of carcinoma erysipelatoides from a teaching hospital in australiac-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarraysFirst-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literatureCirculating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer.Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancerInflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
P2860
Q21195182-D40F222D-73B3-45A0-9EDB-7FF90886649AQ24548312-5596EF2D-04A1-4910-8A61-5C7EC753B085Q24598488-06FBBA74-9C78-4434-8F62-60D67146AC3EQ24794280-BBE6C714-546E-4EE6-8DC4-F9557288FCADQ24797853-3F6554F8-2D7A-4974-BA2D-E9CFF887AB06Q24801016-E4402F65-2963-400B-BB21-E670F9CC991DQ26739398-DAF07A9D-5EEA-4C72-9143-FDB2424658E0Q26748804-0B4E160E-396B-468A-AEFF-9D0D613303A0Q26799560-51B5ACC9-39FF-4D31-87B4-3E41DE11D957Q27027856-7BF91081-69F4-4C4F-98BA-B4015B9B9311Q28075322-2A5B770F-A759-4E78-A6EC-843CEC2B1943Q30424533-2AE279DE-CE2B-4B5B-AAB5-D6F9F65F14E0Q30596741-38EED4AA-9B61-4AE4-8652-EE1AA9170E0EQ30820946-54608048-C869-4E55-983D-788323A68966Q33318125-A132EC86-EB51-4E8E-8D46-A6232FF5AE15Q33689442-9ABA00AA-7378-4895-8EB6-6A28AC65F386Q33770856-FB9839B4-C7BE-4B17-A75E-0FB2FA397E3CQ34129423-073F864B-74E8-4778-B768-B393FF3E1757Q34147662-8355326C-DD23-47B0-9D1D-D33C8D519AECQ34478105-88D07936-D1CE-4441-A1A6-65EECBD08D9CQ34743442-AB04CBF4-0D3A-4386-98B3-C837DD33A282Q34753009-B1B83593-1DAE-44A4-A736-BBBC0B3BF401Q34770011-53F9F697-C6EC-4BA8-852C-A36B17FAE269Q34785853-5C886708-F5C4-4272-8DD5-0CF8D7120FB5Q35007782-A21E72D3-166D-4B6B-B85D-0D507682DBA7Q35115896-B6F6217F-F9F6-4799-A29E-DA97BFA13E1BQ35572495-93C0D769-D702-4AA4-AE73-E9F625122AFFQ35624765-ECB26F5C-1AFC-4744-B29D-782F8C2A9FD9Q35667692-FB10D858-955F-4CF9-A926-39CDF8B34D0FQ35890623-989FF97F-E728-4A65-BB51-2BE7F76FBA3BQ35979192-0372FE2B-B09F-4C8B-B1AD-4A0F7657D078Q36519740-A59F6892-6E67-475C-A276-49680E8B01F0Q36609706-B85DF7E9-2800-4387-BDBA-FBE073D9E8D4Q36619863-16739915-45D3-4E0A-B0DD-BBCE940A9F4DQ36646442-3E49EA59-1E7E-410A-B5C0-949691EAC8B5Q36825817-D88FC91C-205F-4D0A-8B12-57F8D4C05225Q36848095-3A5AE7B9-695E-40ED-A4D3-D1371805190DQ37085828-43488DE7-2522-4AC8-BEF0-1F3B60461EB1Q37165892-1010A159-35AA-4176-923A-CD4C43BA7599Q37362586-D4289702-295B-433F-923E-F833332DAFAA
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Inflammatory breast cancer: a review.
@ast
Inflammatory breast cancer: a review.
@en
type
label
Inflammatory breast cancer: a review.
@ast
Inflammatory breast cancer: a review.
@en
prefLabel
Inflammatory breast cancer: a review.
@ast
Inflammatory breast cancer: a review.
@en
P2093
P1476
Inflammatory breast cancer: a review.
@en
P2093
A U Buzdar
G Hortobagyi
I A Jaiyesimi
P304
P356
10.1200/JCO.1992.10.6.1014
P407
P577
1992-06-01T00:00:00Z